gsk1278863 and Liver-Diseases

gsk1278863 has been researched along with Liver-Diseases* in 1 studies

Other Studies

1 other study(ies) available for gsk1278863 and Liver-Diseases

Article	Year
Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:5 Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor in development for treatment of anemia of chronic kidney disease. We evaluated the role of hepatic impairment on daprodustat pharmacokinetics, pharmacodynamics, and tolerability. Participants with mild (Child-Pugh Class A, score 5-6) and moderate (Child-Pugh Class B, score 7-9) hepatic impairment and matched healthy controls were administered single 6-mg doses of daprodustat. Exposure parameters were determined for daprodustat and its six metabolites. Comparisons resulted in 1.5- and 2.0-fold higher daprodustat C Topics: Barbiturates; Female; Glycine; Humans; Liver Diseases; Male; Prolyl-Hydroxylase Inhibitors	2022

Article

Year

Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function.

Clinical pharmacology in drug development, 2022, Volume: 11, Issue:5

Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor in development for treatment of anemia of chronic kidney disease. We evaluated the role of hepatic impairment on daprodustat pharmacokinetics, pharmacodynamics, and tolerability. Participants with mild (Child-Pugh Class A, score 5-6) and moderate (Child-Pugh Class B, score 7-9) hepatic impairment and matched healthy controls were administered single 6-mg doses of daprodustat. Exposure parameters were determined for daprodustat and its six metabolites. Comparisons resulted in 1.5- and 2.0-fold higher daprodustat C

Topics: Barbiturates; Female; Glycine; Humans; Liver Diseases; Male; Prolyl-Hydroxylase Inhibitors

2022